190017-00-6
Chemical Structure
Correolide
- CAS No.: 190017-00-6
- Formula:C40H52O16
- Molecular Weight:788.83
InChIKey: VKDXHXWBOARFPD-IHWRNOMOSA-N
SMILES: COC([C@]12[C@]3([C@]([C@@]4([H])[C@]([C@@H]([C@@H]3OC(C)=O)OC(C)=O)([C@]5([H])[C@@](CC4)([C@@]6([H])[C@@]([C@H]([C@H]5OC(C)=O)OC(C)=O)(COC(C=C6)=O)C(C)OC(C)=O)C)C)(CC([C@@]1([H])O2)=C)O)C)=O
Biological Activity: Correolide is a pentacyclic nortriterpene isolated from Spachea correa. Correolide blocks Kv1 family voltage-gated potassium channels (Kv1.3 Kd = 90 nM) and acts on the inner pore between the selectivity filter and the activation gate, thereby inhibiting T cell proliferation and modulating vascular tone. Correolide can be used in research on delayed-type hypersensitivity and autoimmune diseases[1][2][3][4][5][6][7][8][9][10].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Correolide | Correolide is a pentacyclic nortriterpene isolated from Spachea correa. Correolide blocks Kv1 family voltage-gated potassium channels (Kv1.3 Kd = 90 nM) and acts on the inner pore between the selectivity filter and the activation gate, thereby inhibiting T cell proliferation and modulating vascular tone. Correolide can be used in research on delayed-type hypersensitivity and autoimmune diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Archer SL, et al. Preferential expression and function of voltage-gated, O2-sensitive K+ channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells. Circulation research. 2004 Aug 6;95(3):308-18.
- [2]. Chandy KG, et al. K+ channels as targets for specific immunomodulation. Trends in pharmacological sciences. 2004 May;25(5):280-9.
- [3]. Baell JB. Potassium channel blockers as immunosuppressants. Expert Opinion on Therapeutic Patents. 2005 Sep 1;15(9):1209-20.
- [4]. Wulff H, et al. K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chemical reviews. 2008 May;108(5):1744.
- [5]. Beeton C, et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Molecular pharmacology. 2005 Apr;67(4):1369-81.
- [6]. Gautier M, et al. Heterogeneous Kv1 function and expression in coronary myocytes from right and left ventricles in rats. American journal of physiology. Heart and circulatory physiology. 2007 Jan;292(1):H475-82.
- [7]. Goodwill AG, et al. Critical contribution of KV1 channels to the regulation of coronary blood flow. Basic research in cardiology. 2016 Sep;111(5):56.
- [8]. Plane F, et al. Heteromultimeric Kv1 channels contribute to myogenic control of arterial diameter. Circulation research. 2005 Feb 04;96(2):216-24.
- [9]. Cheong A, et al. Expression and function of native potassium channel [K(V)alpha1] subunits in terminal arterioles of rabbit. J Physiol. 2001 Aug 1;534(Pt 3):691-700.
- [10]. Davies AM, et al. Potassium channel KV alpha1 subunit expression and function in human detrusor muscle. J Urol. 2002 Apr;167(4):1881-6.
